Donor-Derived Cell-Free DNA in Plasma as a Non-Invasive Marker of Graft Rejection in Liver Transplant Recipients: A Review
DOI:
https://doi.org/10.5281/zenodo.22207652Keywords:
Liver Transplantation, Cell-Free DNA, Graft Rejection, Non-Invasive Biomarker, Droplet Digital PCRAbstract
Rejection after liver transplantation is confirmed by biopsy, an invasive procedure with its own sampling error. Donor DNA circulating in recipient lasma offers a measurement of graft injury that can be repeated as often as a blood test. The accuracy is good; the threshold at which it becomes a decision is not settled. Objectives: To review the published evidence on donor-derived cell-free DNA as a marker of graft rejection after liver transplantation: how it is measured, what accuracy it achieves against biopsy, how it compares with liver function tests, and why thresholds differ so widely between studies. Material and Methods: Narrative review of prospective cohort studies, assay validation reports, cross-organ comparisons and methodological papers indexed in PubMed and the major transplantation and clinical chemistry journals. Studies were eligible if they reported the performance of donor-derived cell-free DNA against a defined rejection endpoint in transplant recipients, or the analytical basis of its measurement. No new patient data were
generated; every estimate quoted is one published by the original investigators. Results: In a prospective multicentre cohort of 115 adult recipients across three centres, graft-derived cell-free DNA measured by droplet digital polymerase chain reaction discriminated rejection with sensitivity of 90.3 per cent (95% CI 74.2-98.0) and specificity of 92.9 per cent (95% CI 89.3-95.6) at a threshold of 10 per cent, outperforming conventional liver function tests on the same samples. In paediatric recipients a threshold of 28.7 per cent
gave an area under the curve of 0.878 (95% CI 0.753-0.954), with positive and negative predictive values of 80 and 92.3 per cent. Serial measurement detected rising concentrations before graft dysfunction was apparent on liver enzymes, and the marker performs comparably in kidney, heart and lung transplantation. Conclusion: Donor-derived cell-free DNA detects graft injury earlier and more specifically than liver function tests, and does so without biopsy. Its principal weakness is that it reports injury rather than its cause, and no threshold has been agreed across studies, with published cut-offs differing almost threefold. Abbreviations: dd-cfDNA – Donor-Derived Cell-Free DNA, GcfDNA – Graft-Derived Cell-Free DNA, cfDNA – Cell-Free DNA, LTx – Liver Transplantation, ddPCR – Droplet Digital Polymerase Chain Reaction, SNP – Single Nucleotide Polymorphism, LFT – Liver Function Test, TCMR – T Cell-Mediated Rejection, AMR – Antibody-Mediated Rejection, AUC – Area Under the Receiver Operating Characteristic Curve, PPV – Positive Predictive Value, NPV – Negative Predictive Value.
References
Lo YMD, Tein MSC, Pang CCP, Yeung CK, Tong KL, Hjelm NM. "Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients". Lancet 351(1998):1329-1330.
Snyder TM, Khush KK, Valantine HA, Quake SR. "Universal noninvasive detection of solid organ transplant rejection". Proc Natl Acad Sci USA 108(2011):6229-6234.
De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al. "Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection". Sci Transl Med 6(2014):241ra77.
Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, Oellerich M. "Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study". PLoS Med 14(2017):e1002286.
Levitsky J, Asrani SK, Schiano T, Moss A, Chavin K, Miller C, et al. "Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation". Am J Transplant 20(2020):2173-2183.
Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, et al. "Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury". Clin Chem 59(2013):1732-1741.
Sharon E, Shi H, Kharbanda S, Koh W, Martin LR, Khush KK, et al. "Quantification of transplant-derived circulating cell-free DNA in absence of a donor genotype". PLoS Comput Biol 13(2017):e1005629.
Gordon PM, Khan A, Sajid U, Chang N, Suresh V, Dimnik L, et al. "An algorithm measuring donor cell-free DNA in plasma of cellular and solid organ transplant recipients that does not require donor or recipient genotyping". Front Cardiovasc Med 3(2016):33.
Sherwood K, Weimer ET. "Characteristics, properties, and potential applications of circulating cell-free DNA in clinical diagnostics: a focus on transplantation". J Immunol Methods 463(2018):27-38.
Grskovic M, Hiller DJ, Eubank LA, Sninsky JJ, Christopherson C, Collins JP, et al. "Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients". J Mol Diagn 18(2016):890-902.
Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, et al. "Cell-free DNA and active rejection in kidney allografts". J Am Soc Nephrol 28(2017):2221-2232.
Richmond ME, Zangwill SD, Kindel SJ, Deshpande SR, Schroder JN, Bichell DP, et al. "Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation". J Heart Lung Transplant 39(2020):454-463.
De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C, et al. "Noninvasive monitoring of infection and rejection after lung transplantation". Proc Natl Acad Sci USA 112(2015):13336-13341.
Levitsky J, Kandpal M, Guo K, Kleiboeker S, Sinha R, Abecassis M. "Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients". Am J Transplant 22(2022):532-540.
Goh SK, Do H, Testro A, Pavlovic J, Vago A, Lokan J, et al. "The measurement of donor-specific cell-free DNA identifies recipients with biopsy-proven acute rejection requiring treatment after liver transplantation". Transplant Direct 5(2019):e462.
Zhao D, Zhou T, Luo Y, Wu C, Xu D, Zhong C, et al. "Preliminary clinical experience applying donor-derived cell-free DNA to discern rejection in pediatric liver transplant recipients". Sci Rep 11(2021):1138.
Fernández-Galán E, Badenas C, Fondevila C, Jiménez W, Navasa M, Puig-Butillé JA, Brunet M. "Monitoring of dd-cfDNA by STRs, concentration of total cfDNA and fragment size for acute rejection risk assessment in liver transplantation". Liver Transpl 28(2022):257-268.
Beck J, Schmitz J, Kanzow P, Kollmar O, Oellerich M, Schütz E. "Absolute quantification of graft derived cell-free DNA early after liver transplantation using droplet digital PCR". Clin Chem 60(2014):S194-S195.
Gielis EM, Ledeganck KJ, De Winter BY, Del Favero J, Bosmans JL, Claas FH, et al. "Cell-free DNA: an upcoming biomarker in transplantation". Am J Transplant 15(2015):2541-2551.
Nakamura K, Kageyama S, Kupiec-Weglinski JW. "Innate immunity in ischemia-reperfusion injury and graft rejection". Curr Opin Organ Transplant 24(2019):687-693.
Levitsky J, Kandpal M, Guo K, Zhao L, Kurian S, Whisenant T, Abecassis M. "Prediction of liver transplant rejection with a biologically relevant gene expression signature". Transplantation 106(2022):1004-1011.
Cucchiari D, Cuadrado-Payan E, Gonzalez-Roca E, Revuelta I, Argudo M, Ramirez-Bajo MJ, et al. "Early kinetics of donor-derived cell-free DNA after transplantation predicts renal graft recovery and long-term function". Nephrol Dial Transplant 39(2024):114-121.
Beck J, Oellerich M, Schulz U, Schauerte V, Reinhard L, Fuchs U, et al. "Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation". Transplant Proc 47(2015):2400-2403.
Oellerich M, Sherwood K, Keown P, Schütz E, Beck J, Stegbauer J, et al. "Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury". Nat Rev Nephrol 17(2021):591-603.
Knight SR, Thorne A, Lo Faro ML. "Donor-specific cell-free DNA as a biomarker in solid organ transplantation: a systematic review". Transplantation 103(2019):273-283.
